FDAnews
www.fdanews.com/articles/108192-hana-biosciences-receives-orphan-drug-designation-for-marqibo

Hana Biosciences Receives Orphan Drug Designation for Marqibo

July 1, 2008

The FDA gave orphan drug designation to Hana Biosciences for Marqibo sulfate injection for the treatment of adult patients with metastatic uveal melanoma.

The company is conducting a Phase II clinical trial to assess the efficacy of the drug as determined by a complete response, partial response or durable stable disease.

Uveal melanoma is a relatively rare cancer — up to 5,000 cases reported per year — that affects the eye, Hana said.